Search

Objectives. To compare the efficacy of the newest cholesterol-lowering drug, rosuvastatin (RSV) with atorvastatin (ATV) in subjects with type 2 diabetes. Design. A 24-week, open-label, randomized, parallel-group, phase IIIb, multicentre study.Setting. Diabetes outpatient clinics of 26 hospitals in the Netherlands.Subjects. A total of 263 patients with type 2 diabetes treated with oral agents or insulin, age (mean SD) 60 10 years, body mass index (BMI) 31.4 +/- 6.1 kg m(-2) 46% males.Intervention. After a 6-week dietary lead-in period, patients were randomized to RSV (n = 13 1) or ATV (n = 132) treatment in a dose escalation scheme (RSV: 10, 20 and 40 mg or ATV: 20, 40 and 80 mg for 6 weeks each sequentially).Main outcome measures. Primary outcome was the change in apolipoprotein B (apoB) and apoB/apolipoprotein Al (apoAl) ratio, which has been suggested a better predictor for cardiovascular events than total (TC) or low-density lipoprotein cholesterol (LDL-C). Secondary outcomes were the changes in other lipid parameters.Results. Baseline LDL-C in the RSV and ATV groups was 4.23 +/- 0.98 mmol L-1 and 4.43 +/- 0.99 mmol L-1, whilst apoB/apoA1 was 0.86 +/- 0.22 and 0.92 +/- 0.35, respectively. A greater reduction in apoB/apoA1 was seen with RSV (-34.91%. -39.2% and -40.5%) than with ATV (-32.4%, -34.7% and -35.8%, P Conclusion. In subjects with type 2 diabetes, greater improvements of apoB/apoA1 and across the lipid profile were observed with RSV compared with ATV.

Objectives. To compare the efficacy of the newest cholesterol-lowering drug, rosuvastatin (RSV) with atorvastatin (ATV) in subjects with type 2 diabetes. Design. A 24-week, open-label, randomized, parallel-group, phase IIIb, multicentre study. Setting. Diabetes outpatient clinics of 26 hospitals in the Netherlands. Subjects. A total of 263 patients with type 2 diabetes treated with oral agents or insulin, age (mean SD) 60 10 years, body mass index (BMI) 31.4 +/- 6.1 kg m(-2) 46% males. Intervention. After a 6-week dietary lead-in period, patients were randomized to RSV (n = 13 1) or ATV (n = 132) treatment in a dose escalation scheme (RSV: 10, 20 and 40 mg or ATV: 20, 40 and 80 mg for 6 weeks each sequentially). Main outcome measures. Primary outcome was the change in apolipoprotein B (apoB) and apoB/apolipoprotein Al (apoAl) ratio, which has been suggested a better predictor for cardiovascular events than total (TC) or low-density lipoprotein cholesterol (LDL-C). Secondary outcomes were the changes in other lipid parameters. Results. Baseline LDL-C in the RSV and ATV groups was 4.23 +/- 0.98 mmol L-1 and 4.43 +/- 0.99 mmol L-1, whilst apoB/apoA1 was 0.86 +/- 0.22 and 0.92 +/- 0.35, respectively. A greater reduction in apoB/apoA1 was seen with RSV (-34.91%. -39.2% and -40.5%) than with ATV (-32.4%, -34.7% and -35.8%, P